24.24
price down icon0.33%   -0.08
after-market After Hours: 24.55 0.31 +1.28%
loading
Catalyst Pharmaceuticals Inc stock is traded at $24.24, with a volume of 654.44K. It is down -0.33% in the last 24 hours and down -0.82% over the past month. Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$24.32
Open:
$24
24h Volume:
654.44K
Relative Volume:
0.54
Market Cap:
$2.96B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
20.54
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+5.03%
1M Performance:
-0.82%
6M Performance:
+19.47%
1Y Performance:
+11.86%
1-Day Range:
Value
$23.63
$24.25
1-Week Range:
Value
$22.27
$24.94
52-Week Range:
Value
$19.05
$26.58

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name
Name
Catalyst Pharmaceuticals Inc
Name
Phone
(305) 529-2522
Name
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Name
Employee
182
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CPRX
Catalyst Pharmaceuticals Inc
24.24 2.97B 460.48M 142.80M 221.79M 1.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.69 117.06B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
759.86 80.87B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
717.80 45.06B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.66 42.51B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.12 32.42B 5.36B 287.73M 924.18M 2.5229

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-04-25 Initiated Robert W. Baird Outperform
Nov-18-24 Initiated Stephens Overweight
Mar-14-24 Initiated Citigroup Buy
Mar-07-24 Initiated BofA Securities Buy
Dec-21-23 Initiated Oppenheimer Outperform
Aug-24-22 Downgrade ROTH Capital Buy → Neutral
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Sep-07-18 Resumed Piper Jaffray Overweight
Oct-05-16 Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16 Downgrade Piper Jaffray Overweight → Neutral
Sep-30-14 Reiterated ROTH Capital Buy
Sep-16-14 Reiterated ROTH Capital Buy
Sep-15-14 Reiterated H.C. Wainwright Buy
Oct-21-13 Reiterated Aegis Capital Buy
Sep-24-13 Initiated Maxim Group Buy
Sep-06-13 Reiterated Aegis Capital Buy
Apr-18-13 Initiated Aegis Capital Buy
Aug-27-12 Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform
Oct-01-09 Upgrade Merriman Sell → Neutral
May-29-09 Downgrade Hapoalim Neutral → Underperform
May-29-09 Downgrade Merriman Curhan Ford Buy → Sell
Dec-15-08 Initiated Merriman Curhan Ford Buy
Nov-28-07 Initiated Rodman & Renshaw Mkt Outperform
Jan-31-07 Initiated Stifel Nicolaus Buy
Jan-05-07 Initiated First Albany Buy
View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

pulisher
Mar 06, 2026

American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Mar 06, 2026
pulisher
Mar 05, 2026

Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView

Mar 05, 2026
pulisher
Mar 05, 2026

Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup - ChartMill

Mar 05, 2026
pulisher
Mar 05, 2026

AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - TradingView

Mar 05, 2026
pulisher
Mar 05, 2026

Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Rafferty Asset Management LLC - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - Finviz

Mar 04, 2026
pulisher
Mar 04, 2026

ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView

Mar 04, 2026
pulisher
Mar 04, 2026

Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance

Mar 04, 2026
pulisher
Mar 04, 2026

Best Value Stocks to Buy for March 4th - Yahoo Finance Singapore

Mar 04, 2026
pulisher
Mar 03, 2026

Catalyst Pharmaceuticals (CPRX) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 03, 2026

CPRX: Citigroup Raises Price Target to $35.00, Maintains Buy Rat - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vanguard Group Inc. - MarketBeat

Mar 03, 2026
pulisher
Mar 02, 2026

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 02, 2026
pulisher
Mar 02, 2026

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Royce & Associates LP - MarketBeat

Mar 01, 2026
pulisher
Mar 01, 2026

Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results - Insider Monkey

Mar 01, 2026
pulisher
Feb 28, 2026

Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns - Yahoo Finance

Feb 28, 2026
pulisher
Feb 28, 2026

Why Catalyst Pharmaceuticals (CPRX) Is Down 5.0% After Issuing 2026 Guidance And Buyback PlanAnd What's Next - Sahm

Feb 28, 2026
pulisher
Feb 27, 2026

CPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 27, 2026
pulisher
Feb 27, 2026

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Feb 27, 2026
pulisher
Feb 26, 2026

Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highli - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

Catalyst Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat

Feb 26, 2026
pulisher
Feb 26, 2026

Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations By Investing.com - Investing.com South Africa

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com India

Feb 26, 2026
pulisher
Feb 26, 2026

Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

Catalyst Pharma Q4 Net Income Slips; Announces FY26 Outlook - RTTNews

Feb 26, 2026
pulisher
Feb 26, 2026

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout - ChartMill

Feb 26, 2026
pulisher
Feb 26, 2026

Catalyst Pharmaceuticals (CPRX) Net Margin Strength Reinforces Bullish Earnings Narrative - Sahm

Feb 26, 2026
pulisher
Feb 26, 2026

Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus

Feb 26, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals (CPRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative

Feb 25, 2026
pulisher
Feb 25, 2026

Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Revenue $152.6M, vs. FactSet Est of $142.7M - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Adjusted EPS $0.68, vs. FactSet Est of $0.59 - marketscreener.com

Feb 25, 2026
pulisher
Feb 25, 2026

Record 2025 growth and 2026 outlook at Catalyst Pharmaceuticals (Nasdaq: CPRX) - Stock Titan

Feb 25, 2026
pulisher
Feb 25, 2026

CPRX | Catalyst Pharmaceutical Inc. FinancialsIncome Statement - Quiver Quantitative

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals Reports Record $589 Million in 2025 Revenues, Projects Continued Growth for 2026 - Quiver Quantitative

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada

Feb 25, 2026
pulisher
Feb 25, 2026

Catalyst: Q4 Financial Results Overview - Bitget

Feb 25, 2026
pulisher
Feb 24, 2026

Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews

Feb 24, 2026
pulisher
Feb 24, 2026

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance

Feb 24, 2026
pulisher
Feb 24, 2026

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - The Manila Times

Feb 24, 2026
pulisher
Feb 24, 2026

Aug Volume: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Upgrade & Verified Chart Pattern Signals - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 23, 2026

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Feb 23, 2026

Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Harper Molly
Director
Dec 12 '25
Sale
23.25
26,746
621,920
2,360
$98.40
price down icon 1.24%
$28.78
price down icon 3.16%
$52.52
price down icon 2.43%
$101.50
price down icon 0.44%
$140.13
price down icon 2.40%
biotechnology ONC
$301.12
price up icon 2.79%
Cap:     |  Volume (24h):